DECLARE-TIMI 58

SGLT2 Inhibitor CVOTs

DECLARE-TIMI 58 CVOT

DECLARE-TIMI 58 Key Baseline Characteristics

DECLARE-TIMI-58 Primary Endpoints

DECLARE-TIMI-58 Renal Composite Endpoint and HHF

DECLARE-TIMI 58 Key Safety Events

Clinical Implications

REDUCE-IT

REDUCE-IT CVOT

REDUCE-IT: Key Baseline Characteristics

REDUCE-IT: Primary Endpoint CV Death, MI, Stroke, Coronary Revasc, Unstable Angina

REDUCE-IT Treatment-Emergent Adverse Events

REDUCE-IT: Secondary Endpoint CV Death, MI, Stroke

Clinical Implications

CIRT

The Inflammatory Hypothesis of Atherosclerosis

JUPITER Trial

Effect of Low-Dose Methotrexate

CIRT Study Design and Key Baseline Characteristics

CIRT Results Part 1, at 8 Months

Inflammation Inhibition in the Absence of Lipid Lowers CV Event Rate

Tying It All Together

Published SGLT2 Inhibitor CVOT Study Cohorts

Published SGLT2 Inhibitor CVOTs Key Characteristics

Pooled Data for the Composite of MACE Myocardial Infarction, Stroke, and CV Death

Pooled Data for the Composite of MACE Stratified by ASCVD vs Multiple Risk Factors

ADA/EASD 2018 Consensus Report for Patients With Established ASCVD, HF, or CKD

Tying It All Together

Abbreviations

Abbreviations (cont)

Abbreviations (cont)